OneMedNet supports mlHealth 360's FDA clearance for AI software detecting intracranial hemorrhage, showcasing the value of high-quality Real-World Data.
Quiver AI Summary
OneMedNet Corporation announced its high-quality, regulatory-grade Real-World Data (RWD) played a crucial role in helping mlHealth 360 secure FDA 510(k) clearance for its AI-powered software, Scaida BrainCT-ICH, designed for rapid detection of intracranial hemorrhage from head CT scans. The AI solution analyzes images in about 5.97 seconds, enhancing clinical triage in acute care environments. OneMedNet’s data, which includes comprehensive electronic medical records (EMR) and diagnostic imaging, was vital for model development and regulatory submission. This achievement underscores OneMedNet's status as a leading RWD provider, reflecting the increasing demand from AI and life science firms relying on their data. Both companies highlight the importance of high-quality data in advancing healthcare innovation and improving patient outcomes.
Potential Positives
- OneMedNet's high-quality Real-World Data significantly contributed to mlHealth 360 obtaining FDA 510(k) clearance for an AI-powered software solution, highlighting the effectiveness and reliability of OneMedNet's data offerings.
- This FDA clearance serves as a validation of OneMedNet’s position as a leading provider of regulatory-grade data, thereby enhancing its reputation and credibility in the healthcare sector.
- The collaboration with mlHealth 360 demonstrates the strong demand for OneMedNet's data services, potentially leading to increased business opportunities and partnerships with other AI and life sciences companies.
Potential Negatives
- The press release includes a cautionary note regarding forward-looking statements, indicating potential risks and uncertainties that could impact the company's ability to execute its strategies and plans.
- The reliance on proprietary data and the competitive nature of the industry may expose the company to risks if it fails to keep pace with new technologies and market needs.
- The mention of risks associated with investing in Digital Assets suggests potential volatility that could affect the company's financial stability and strategy execution.
FAQ
What is OneMedNet Corporation known for?
OneMedNet Corporation is a leading provider of regulatory-grade, AI-ready Real-World Data for the healthcare industry.
What product did mlHealth 360 receive FDA clearance for?
mlHealth 360 received FDA clearance for Scaida BrainCT-ICH, an AI-powered software to detect intracranial hemorrhage.
How does Scaida BrainCT-ICH assist medical professionals?
Scaida BrainCT-ICH analyzes head CT images and identifies suspected intracranial hemorrhage in approximately 5.97 seconds.
What role did OneMedNet's data play in FDA clearance?
OneMedNet’s regulatory-grade Real-World Data was critical in supporting model development, validation, and regulatory submission for Scaida BrainCT-ICH.
Why is high-quality data important in healthcare innovation?
High-quality data accelerates meaningful innovation and supports better regulatory outcomes, confirmed by successful collaborations like with mlHealth 360.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ONMD Insider Trading Activity
$ONMD insiders have traded $ONMD stock on the open market 22 times in the past 6 months. Of those trades, 20 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ONMD stock by insiders over the last 6 months:
- THOMAS KOSASA has made 2 purchases buying 587,395 shares for an estimated $505,598 and 0 sales.
- JEFFREY YU (Chief Medical Officer) has made 17 purchases buying 343,813 shares for an estimated $259,585 and 0 sales.
- AARON GREEN (Chief Executive Officer) has made 0 purchases and 2 sales selling 126,322 shares for an estimated $218,624.
- ERIC CASABURI purchased 10,000 shares for an estimated $30,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ONMD Hedge Fund Activity
We have seen 11 institutional investors add shares of $ONMD stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CORRECT CAPITAL WEALTH MANAGEMENT added 4,504,955 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,910,400
- EXENCIAL WEALTH ADVISORS, LLC added 2,107,598 shares (+141.3%) to their portfolio in Q3 2025, for an estimated $2,297,281
- VANGUARD GROUP INC added 234,739 shares (+31.4%) to their portfolio in Q3 2025, for an estimated $255,865
- HRT FINANCIAL LP removed 182,638 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $199,075
- GEODE CAPITAL MANAGEMENT, LLC added 174,885 shares (+128.0%) to their portfolio in Q3 2025, for an estimated $190,624
- GOLDMAN SACHS GROUP INC added 56,584 shares (+inf%) to their portfolio in Q3 2025, for an estimated $61,676
- NORTHERN TRUST CORP added 40,973 shares (+192.3%) to their portfolio in Q3 2025, for an estimated $44,660
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced that its high-quality, multimodal clinical data supported mlHealth 360 in obtaining U.S. Food and Drug Administration (FDA) 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software solution designed to facilitate the rapid detection of intracranial hemorrhage (ICH) from head computed tomography (CT) scans.
Scaida BrainCT-ICH leverages artificial intelligence to analyze head CT images and identify suspected intracranial hemorrhage in approximately 5.97 seconds after image acquisition, enabling faster clinical triage and supporting timely decision-making in acute care settings, according to mlHealth 360.
OneMedNet’s regulatory-grade Real-World Data—spanning longitudinal electronic medical records (EMR), diagnostic imaging, and associated clinical reports—played a critical role in supporting model development, validation, and regulatory submission.
This milestone serves as a clear proof point of OneMedNet’s establishment as a leading Real-World Data provider, as an increasing number of life science and AI companies rely on OneMedNet to support FDA submissions. The depth, diversity, and quality of OneMedNet’s curated imaging and clinical datasets enabled mlHealth 360 to access fit-for-purpose data without compromising data integrity or regulatory compliance—reinforcing a strong correlation between high-quality data, successful regulatory outcomes, and sustained demand from new and repeat customers.
Aaron Green, CEO and President of OneMedNet, stated, “We are proud to collaborate with our premier partner mlHealth 360 and to support their efforts in advancing patient care through clinically impactful AI. Seeing OneMedNet’s regulatory-grade Real-World Data—enriched with medical imaging and EMR context—contribute directly to an FDA-cleared solution reinforces the value of high-quality data in accelerating meaningful innovation. This collaboration highlights our mission to responsibly unlock healthcare data and enable partners like mlHealth 360 to deliver better outcomes at scale.”
Kumar Surender Sinwar, CEO of mlHealth 360, added, “We knew early on that partnering with OneMedNet was the right decision. Their ability to provide immediate access to high-quality, regulatory-grade imaging and clinical data meant we could focus on building and validating our AI without worrying about data quality, completeness, or compliance. That confidence was essential in getting Scaida BrainCT-ICH to FDA clearance.”
The FDA clearance of Scaida BrainCT-ICH highlights the growing role of Real-World Data in enabling next-generation medical AI, particularly in time-sensitive clinical applications such as stroke and trauma care. For OneMedNet, this milestone further validates the company’s differentiated data platform and its expanding role as a trusted data partner for regulated AI and life-sciences innovation.
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.
About mlHealth 360
mlHealth 360 is a healthcare AI and analytics company dedicated to transforming the future of medical imaging through secure, HIPAA-compliant, cloud-native solutions. Our advanced platform acts as a force multiplier for radiologists, delivering intelligent case triage, anomaly detection, and automated report generation—reducing diagnostic turnaround times and enhancing clinical decision-making. Designed for seamless integration with existing hospital systems, mlHealth360 offers scalable deployment across both cloud and on-premises environments.
With a growing network of healthcare partners across North America and Asia, mlHealth360 is driven by its core philosophy of Infinite Insight—turning complex medical data into actionable intelligence that empowers clinicians and improves patient outcomes.
Learn more at www.mlhealth360.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
SOURCE: ONEMEDNET CORPORATION